US Stock MarketDetailed Quotes

FULC Fulcrum Therapeutics

Watchlist
  • 4.350
  • +0.320+7.94%
Close Dec 20 16:00 ET
  • 4.350
  • 0.0000.00%
Post 18:05 ET
234.63MMarket Cap-15.00P/E (TTM)

Fulcrum Therapeutics Key Stats

Fulcrum Therapeutics Q3 2024 Earnings Date

Currency:USDNov 13, 2024

Estimate
(YoY)
Actual
(YoY)
Vs Estimate
(% Chg)
Revenue
0
0
0
-100.00%
-100.00%
--
EPS
-0.40
-0.35
+0.05
Beat Est.
-2.56%
+10.26%
+12.48%
Buy

Dec 21, 2024

Fulcrum Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 4 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Jul 31, 20242024/Q280.000M / 41.113M--
May 13, 20242024/Q10.000 / 360.140K--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 0.000--
--2024/Q4-- / 0.000--
Nov 13, 20242024/Q30.000 / 0.000--
Jul 31, 20242024/Q280.000M / 41.113M--
May 13, 20242024/Q10.000 / 360.140K--

Unlock Free Earnings Estimates

Fulcrum Therapeutics Earnings Reports

Read more

Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Dec 21, 2024

Buy

  • Buy

    25.00%
  • Hold

    75.00%
  • Sell

    0.00%

Price Target

No Data